Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige

Latest Out-Licensing Deal Signed By Prestige BioPharma

Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.

Israeli Flag in Jerusalem, israel
Prestige CEO Lisa Park has declared HD201, “The most equivalent biosimilar of Herceptin.” • Source: Shutterstock

Teva has joined forces with Prestige Biopharma, picking up exclusive rights for the supply and commercialization of the Singapore-based firm’s HD201 trastuzumab biosimilar in Teva’s native Israel.

The partnership, signed between Prestige BioPharma and Abic Marketing, which operates under the brand of Teva Israel, will leverage Teva’s...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.